INmune Bio's ATM offering raises $19M ahead of Phase II results, but disappointing data and dilution signal risks. Read here ...

Cassava Sciences (SAVA) announced that the Company presented a poster at the TSC International Research Conference held June 26-28, 2025 in ...

Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human safety data fro ...

Cassava Sciences’ stock (NASDAQ: SAVA) plummeted on Monday by a staggering 85%. “The results are disappointing for patients and their families who are living with this disease and physicians ...

Cassava Sciences, Inc. reported $121.1m of cash and a net loss of $(97.2m) for the year 2023. The company's research and development expenses increased to $89.4m in 2023.

Shares of Cassava Sciences (SAVA 2.83%) skyrocketed in the first half of 2021. The biotech's share price ran up 1,152% from the first of January to the end of June.

Biotechnology company Cassava Sciences (NASDAQ:SAVA) has only two primary product candidates, but they’re highly significant. SAVA stock holders, like all biotech-sector investors, should stay ...

After surging from $7 per share to around $120 per share this year, Cassava Sciences (NASDAQ:SAVA) stock may not have room to make more “to the moon” moves higher. Source: Atthapon Raksthaput ...

The market's been in love with Cassava Sciences (SAVA 2.83%) all year, but it's definitely a rocky relationship. The stock soared from $8 a share back in January to $126 on Aug. 12.